Directed evolution of therapeutic antibodies targeting glycosylation in cancer

Ron Amon, Ronit Rosenfeld, Shahar Perlmutter, Oliver C. Grant, Sharon Yehuda, Aliza Borenstein-Katz, Ron Alcalay, Tal Marshanski, Hai Yu, Ron Diskin, Robert J. Woods, Xi Chen, Vered Padler-Karavani*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Glycosylation patterns commonly change in cancer, resulting in expression of tumor-associated carbohydrate antigens (TACA). While promising, currently available anti-glycan antibodies are not useful for clinical cancer therapy. Here, we show that potent anti-glycan antibodies can be engineered to acquire cancer therapeutic efficacy. We designed yeast surface display to generate and select for therapeutic antibodies against the TACA SLea (CA19−9) in colon and pancreatic cancers. Elite clones showed increased affinity, better specificity, improved binding of human pancreatic and colon cancer cell lines, and increased complement-dependent therapeutic efficacy. Molecular modeling explained the structural basis for improved antibody functionality at the molecular level. These new tools of directed molecular evolution and selection for effective anti-glycan antibodies, provide insights into the mechanisms of cancer therapy targeting glycosylation, and provide major methodological advances that are likely to open up innovative avenues of research in the field of cancer theranostics.

Original languageEnglish
Article number2824
Pages (from-to)1-19
Number of pages19
Issue number10
StatePublished - Oct 2020


  • Antibodies
  • Cancer
  • Carbohydrate
  • Glycosylation
  • Nanoparticle
  • Nanoprint
  • Polymer
  • Tumor


Dive into the research topics of 'Directed evolution of therapeutic antibodies targeting glycosylation in cancer'. Together they form a unique fingerprint.

Cite this